Antiplatelet and Anticoagulation Therapies

The Medicines Company announced the approval of cangrelor (Kengreal) by the U.S. Food and Drug Administration (FDA) as an adjunctive therapy to percutaneous coronary intervention (PCI). The novel, intravenous antiplatelet...

A risk assessment algorithm combining clinical risk factors and platelet function test results may help interventional cardiologists better identify patients who stand to benefit from intensive antiplatelet medication after percutaneous coronary i...

People with acute coronary syndrome (ACS) who undergo an angioplasty procedure and receive a heart stent are prescribed an oral antiplatelet (OAP) therapy and aspirin to help prevent a heart attack, a blood clot in their heart stent (stent thrombo...

The Medicines Company announced that the U.S. Food and Drug Administration (FDA) Cardiovascular and Renal Drugs Advisory Committee (CRDAC) voted 9 - 2 with one abstention to recommend approval of the investigational intravenous antiplatelet agent...

cangrelor, Kangreal, FDA approval, The Medicines Company, antiplatelet agent
The Medicines Company announced the approval of cangrelor (Kengreal) by the U.S. Food and Drug Administration (FDA) as an adjunctive...
Patients who received a bare metal coronary stent did not display significant differences in rates of adverse events with an additional 18 months of dual...
Brilinta, Ticagrelor, PEGASUS TIMI-54, ACC, results
AstraZeneca announced full results from the PEGASUS-TIMI 54 study, a large-scale outcomes trial investigating Brilinta (ticagrelor) tablets plus low dose...
rivaroxaban, Xarelto, VENTURE-AF, VKA, atrial fibrillation, Heart Rhythm 2015
Janssen Pharmaceuticals Inc. and its development partner Bayer HealthCare announced results from the VENTURE-AF trial. The study explored the potential of once...
cangrelor, Kangreal, FDA approval, The Medicines Company, antiplatelet agent
Cangrelor (Kengreal) from The Medicines Company is a novel intravenous antiplatelet agent indicated as an adjunctive therapy to
Ticagrelor (Brilinta) 90 mg tablets from AstraZeneca now have FDA approval to be crushed and administered in water by swallowing or via...
The Watchman left atrial appendage closure device from Boston Scientific Corp. is a catheter-delivered heart implant designed to close the...
The Xarelto Starter Pack from Janssen Pharmaceuticals Inc. was designed to help simplify the dosing for the initial 30-day treatment period...

Articles

cangrelor, Kangreal, FDA approval, The Medicines Company, antiplatelet agent
The Medicines Company announced the approval of cangrelor (Kengreal) by the U.S. Food and Drug Administration (FDA) as an adjunctive...
Brilinta, Ticagrelor, PEGASUS TIMI-54, ACC, results
AstraZeneca announced full results from the PEGASUS-TIMI 54 study, a large-scale outcomes trial investigating Brilinta (ticagrelor) tablets plus low dose...
antiplatelet medication, prasugrel, clopidogrel, risk algorithm, SCAI
A risk assessment algorithm combining clinical risk factors and platelet function test results may help interventional cardiologists better identify patients...
PROMETHEUS, prasugrel, clopidogrel, heart disease, bleeding, SCAI
Prasugrel (Effient) is more likely to be given to lower-risk heart disease patients undergoing percutaneous coronary intervention (PCI) compared to clopidogrel...

Video Center

Here are a few observations on cardiovascular ultrasound advances I made while attending the 2015...
5 days 10 hours ago
The latest advances in cardiovascular echocardiography will be presented at the 2015 American...
3 weeks 1 day ago
There were several technology takeaway messages for the future of electrophysiology (EP) at the...
6 weeks 1 day ago
Centricity, webinar, ZFV, ZFP, viewer, remote viewing system, enterprise
Healthcare organizations are demanding more capabilities for image viewers accessed by clinicians. Zero footprint (ZFP) viewers provide imaging tools from...
The webinar "State of the Art in MRI Pediatric Brain Perfusion Imaging" educates participants about the state of the art clinical and emerging translational...
This webinar discusses why contemporary adult cardiac interventions require significant ionizing radiation with potential health risks to both the patient and...

Comparison Charts

Sorry there is no data available